Oligoprogression: Treating the One Spot That Grew — What the Options Actually Are

Oligoprogression is when the cancer grows at one or a few sites while the rest of the disease stays controlled on the same treatment. Most teams work with a limit of one to three progressing sites, and some consider up to five. It is assessed differently from progression across the body, because the treatment you are on is still working everywhere else.

That distinction is the whole reason this page exists. A scan report that says one deposit has enlarged while everything else is stable is not the same report as one that says several areas have grown. Switching systemic treatment because of a single site means giving up a drug that is still holding the rest of the disease. Treating that one site locally, and carrying on with the drug, is the alternative that the term “oligoprogression” was coined to describe.

The count is not the only thing that matters. Your oncologist will also look at how quickly the site appeared, whether it is causing symptoms, how long the treatment has been working, and whether the site can be treated safely. Two deposits enlarging slowly in someone who feels well is a different situation from two appearing within weeks alongside new pain or breathlessness.

Nothing here is a recommendation for your own situation. Whether this applies to you depends on your cancer type, what the report actually says, what treatment you have already had, and how you are day to day — all of which your treating oncologist has in front of them and this page does not.

Often, yes — it is one of the main options on the table. Focused radiation, most commonly stereotactic body radiotherapy (SBRT), can be aimed at the single growing site while systemic treatment continues. Whether it fits depends on where the site is, how large it is, what sits next to it, and whether that area has been irradiated before.

What SBRT actually is. It delivers a high dose to a small, precisely defined target over a small number of sessions — commonly between one and eight — rather than the daily treatment over several weeks that most people picture when they hear the word radiotherapy. Breathing motion is accounted for in the plan so the dose stays on target. Lung, liver, adrenal, spine and bone deposits are the sites most often treated this way; deposits in the brain are handled with stereotactic radiosurgery, which is planned differently. Surgery and thermal ablation are alternatives for some sites and are worth asking about by name.

Where it is delivered. Radiotherapy is delivered at NABH-accredited partner centres. CION Cancer Clinics does not own a linear accelerator or an SBRT platform; CION coordinates the treatment plan, the multidisciplinary discussion, the oncology team and your care throughout. Immunotherapy itself is given as day care at CION centres, and response-assessment PET-CT is coordinated at partner imaging centres rather than provided in-house.

How settled is the evidence? Local treatment for oligoprogressive disease is discussed by guideline bodies including NCCN, ESMO and ASCO, and it is an area of active study rather than settled practice in every cancer type. The evidence is stronger in some cancers than others. Ask your oncologist what the evidence looks like for your cancer specifically, and treat any source that answers this question with a single confident number with caution. We go into the radiotherapy side in more depth in SBRT for Oligometastatic Disease, and into how the two treatments interact in Immunotherapy With Radiation: Does One Help the Other?

• More than a few sites are growing — once several areas are progressing at once, the disease is telling you something about the whole body rather than one spot, and the discussion moves to systemic options.
• The progression has come quickly — new deposits appearing within weeks behave differently from a single site enlarging slowly over months. Ask what the pace means for what is being proposed next.
• The site cannot be treated safely — proximity to bowel, spinal cord, airway or a previously irradiated volume can put a safe dose out of reach. A radiation oncologist decides this, not a scan report.
• Day-to-day function has dropped — how much of the day is spent resting rather than up and about changes both eligibility and tolerance. Ask where you sit on the performance-status scale and what it means for the options.
• The patient does not want more treatment — this is not something to talk someone out of. It is information, and it belongs in front of the oncology team as clearly as any scan result.

None of these closes the conversation. They change what the conversation is about.

Usually yes, when the rest of the disease is still controlled. Keeping a systemic treatment that is still working elsewhere is the entire point of treating one site locally. Some teams hold a cycle around the radiation and some do not. That decision turns on which site is being treated and on how you have tolerated the drug so far.

Watch for overlapping side effects, and report them early. Radiation to the chest in someone on a checkpoint inhibitor is the clearest example: breathlessness or a new, persistent dry cough can come from either the radiation or an immune-related reaction in the lungs, and the two are told apart with imaging and review, not at home. New or worsening breathlessness is not something to sit on until the next cycle. Call your treating team, or the CION helpline on 1800 202 8726, and say clearly that you are on immunotherapy and have recently had radiotherapy.

Know what would count as the plan not working. Ask your oncologist, before the radiation, what the next scan needs to show for the current drug to continue, and what result would move the conversation to a different systemic treatment. If new sites appear while the treated one settles, that is information about the whole disease rather than about the radiation.

If it turns out that several sites are progressing rather than one, the question changes shape entirely, and Immunotherapy Has Stopped Working: What Now? covers what usually follows. If a different systemic treatment is being weighed after that, Deciding Whether to Start a Third or Fourth Line of Treatment sets out how to think about expected benefit honestly.

Alongside treatment, not after it. Palliative care is symptom-focused care — pain, breathlessness, appetite, sleep and the family’s own load. It runs in parallel with anti-cancer treatment. Asking for it while a single site is being treated does not withdraw your treatment and does not signal that anyone has decided to stop.

The misunderstanding is common and it costs families a great deal. Many hear the word “palliative” and hear “the end”, so a referral is refused, and symptom support that could have started months earlier arrives in a hurry at the worst possible moment. Guideline bodies including ASCO recommend introducing palliative care alongside standard oncology care in advanced cancer, not only at the very end. A referral at the point where progression is first being discussed is ordinary practice. Palliative Care Alongside Immunotherapy, Not Instead of It explains what the team does and how to ask.

And the goal comes before the treatment. Families who find these decisions least agonising agree first on what matters most right now — more time at home, fewer hospital visits, better symptom control — and only then ask which option serves that goal. Deciding not to pursue local treatment, or to stop disease-directed treatment altogether, is a considered medical decision rather than giving up, and care continues either way. Stopping Treatment: How Families Reach the Decision walks through how that conversation usually goes.

Cost is a fair part of this conversation too. Local radiotherapy, continued immunotherapy cycles and response-assessment imaging are billed separately, and any estimate you are given is indicative, as of August 2026. Ask for it in writing, and ask what ArogyaSri, CGHS or your policy covers for this specific plan.

• If the scan turns out to show more than one or two growing sites, Immunotherapy Has Stopped Working: What Now? sets out what the options are once the pattern is no longer limited.
• If a different systemic treatment is being weighed, Deciding Whether to Start a Third or Fourth Line of Treatment gives an honest framework for expected benefit, cost and the option of stopping.
• If someone in the family is asking whether starting immunotherapy this far along still makes sense at all, Is It Too Late to Start Immunotherapy? answers that directly.
• For the radiotherapy side of this decision in detail, read SBRT for Oligometastatic Disease, and for the wider picture start at the Immunotherapy at CION Cancer Clinics hub.

Weighing this for someone in your own family? Request a free second opinion and a medical oncologist will go through what the report shows, whether local treatment fits, and what happens to the immunotherapy either way.